 AUSTIN, Texas, July 28, 2020 GLOBE NEWSWIRE -- Lumos Pharma, Inc. NASDAQ:LUMO, a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2020 financial results after market close on Thursday, August 13, 2020. The company will host a conference call and webcast at 4:30 PM ET that day to discuss its second quarter financial results and provide an update on corporate activities. There will also be a question and answer session following the prepared remarks. Investors and the general public are invited to listen to a live audio webcast of the conference call, which can be accessed five minutes prior to the start of the call by dialing 855 469-0612 U.S. or 484 756-4268 international. The conference call will be webcast live and a link can be accessed through the Lumos Pharma website at A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing 855 859-2056 U.S. or 404 537-3406 international and using the passcode: 9585725.About Lumos PharmaLumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates NEA, Santé Ventures, and UCB. Lumos Pharmas lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency PGHD. If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit Media Contact:Lisa Miller Lumos Pharma Investor Relations 512-648-3757 Lumos Pharma, Inc. 